Non Small Cell Lung Cancer Clinical Trials in Charlotte, North Carolina

6 studies are recruiting for non small cell lung cancer in Charlotte, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

   Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) muta…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Levine Cancer Institute, Charlotte, North Carolina

   Locations

   203 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT07195695 on ClinicalTrials.gov

2. First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

   Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutati…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Levine Cancer Institute - Charlotte, Charlotte, North Carolina

   Locations

   32 in total

   Run by

   Pierre Fabre Medicament

   See if you can join NCT06043817 on ClinicalTrials.gov

3. Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

   The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Local Institution - 0385, Charlotte, North Carolina

   Locations

   204 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07680790 on ClinicalTrials.gov

4. Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

   Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (N…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Carolinas Medical Center, Charlotte, North Carolina

   Locations

   159 in total

   Run by

   Nuvalent Inc.

   See if you can join NCT06765109 on ClinicalTrials.gov

5. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

   Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Charlotte, North Carolina

   Locations

   20 in total

   Run by

   AstraZeneca

   See if you can join NCT05877599 on ClinicalTrials.gov

6. Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study

   The purpose of this research is to understand cancer related fatigue in patients with non-small cell lung cancer (NSCLC), who are being treated with an immune checkpoint inhibitor.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Atrium Health Levine Cancer, Charlotte, North Carolina

   Locations

   2 in total

   Run by

   Wake Forest University Health Sciences

   See if you can join NCT06567704 on ClinicalTrials.gov